Clinical Trial Update: A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder [Phase 3]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 3 study assessing how long it takes patients to relapse after switching from an oral antipsychotic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 3 | Status: COMPLETED